Pfizer plans to sell Covid vaccines at $110 to $130 per dose News

Pfizer plans to sell Covid vaccines at $110 to $130 per dose News

Pfizer plans to sell Covid vaccines at $110 to $130 per dose News HEAD TOPICS

Pfizer plans to sell Covid vaccines at $110 to $130 per dose

10/21/2022 7:13:00 PM

Pfizer plans to sell Covid vaccines at $110 to $130 per dose

News

Source

NBC News Health

Pfizer plans to sell Covid vaccines at $110 to $130 per dose The estimated price tag is the list price, meaning people with health insurance are likely to pay only a fraction of that cost or nothing at all. ByThe estimated price for Pfizer’s shot is in line with other adult vaccinations, such as for hepatitis and shingles, which can range from as little as $13 to more than $200,The $110 to $130 price tag is the list price, meaning people with Medicare or private health insurance would most likely pay only a fraction of that cost or nothing at all, said Cynthia Cox, vice president and director for the program on the Affordable Care Act for KFF, also known as the Kaiser Family Foundation. Insurers, Cox noted, had been expecting the price to be around $100. Read more:
NBC News Health » Pfizer sets new prices for its COVID-19 vaccines. The cost? $110 to $130 per dose Pfizer says COVID-19 vaccine will cost $110-$130 per dose Pfizer says COVID-19 vaccine will cost $110-$130 per dose Pfizer says COVID-19 vaccine will cost $110-$130 per dose

Wildfires Erupt in the Pacific Northwest

A series of recent wildfires ignited or spread this past week as warm, dry, and windy conditions—a rarity for the rainy Pacific Northwest. Read more >> Pfizer sets new prices for its COVID-19 vaccines. The cost? $110 to $130 per dosePfizer and BioNTech are currently paid $30.50 per COVID vaccine dose by the U.S. government. The price will skyrocket if the emergency declaration in the U.S. isn’t renewed next year. why is cost tied to “emergency” status? The additional $80 pays for lawsuits? With each jab my balls double in size, whose going to be responsible when I have to waddle around to get around!! Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer said the commercial pricing for adult COVID-19 vaccine doses could start in early 2023, depending on when the U.S. government phases out its program of buying the shots. FOX13 🤣🤣🤣 Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots. Some will get it for free. Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots. The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. A nurse in London administers the Pfizer-BioNTech Covid vaccine in December 2020.Pfizer Inc., but the drugmaker says it expects many people will continue receiving it for free.Email article FILE - In this photo illustration, a COVID-19 vaccine is seen with the Pfizer logo in the background. Frank Augstein / AP Oct. 21, 2022, 3:52 PM UTC By Berkeley Lovelace Jr.08% said Thursday that it plans to sell the COVID-19 shot it developed with BioNTech SE BNTX, +8. Pfizer plans to sell the Covid vaccine it developed with BioNTech at $110 to $130 per dose for teens and adults once the U. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses.S.S. government stops paying for them, the drugmaker said Friday. The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The estimated price for Pfizer’s shot is in line with other adult vaccinations, such as for hepatitis and shingles, which can range from as little as $13 to more than $200, according to the Centers for Disease Control and Prevention . Pfizer and BioNTech are currently paid $30. residents with no insurance to get the shots. The $110 to $130 price tag is the list price, meaning people with Medicare or private health insurance would most likely pay only a fraction of that cost or nothing at all, said Cynthia Cox, vice president and director for the program on the Affordable Care Act for KFF, also known as the Kaiser Family Foundation. Insurers, Cox noted, had been expecting the price to be around $100.S. Pfizer said the price takes into account the “value” of the vaccine as well as the cost it takes to make it.” Pfizer’s two-shot vaccine debuted in late 2020 and is easily the most common preventive shot that has been used to fight COVID-19 in the U. The shots will be packaged in a single-dose vial, the company said, rather than the multi-dose vials that have been used throughout the pandemic. MRNA, +7. RELATED: US warned to prepare as COVID cases rise in Europe A Pfizer executive said Thursday that the price reflects increased costs for switching to single-dose vials and commercial distribution. Cox said that once the federal government stops paying for the shots, people will most likely need to get the shots administered at an in-network pharmacy or clinic; otherwise, they might be on the hook for the full list price. Since the start of the pandemic, the government has provided Americans with free Covid tests, vaccines and treatment , through a combination of funding from Congress and other government programs. NVAX, +6.S. But officials have said that as the nation transitions out of the emergency phase of the pandemic and Covid supplies , Covid prevention and care will need to move to the commercial market, most likely starting in the new year. The government has already stopped providing free Covid tests.S. The private market and federal agencies have been preparing for the change. The vaccine brought in $36.S. A CDC advisory committee voted Wednesday , a federal plan that provides free vaccines to children eligible for or covered by Medicaid. The emergency declaration in the U. The move would allow uninsured or underinsured children to receive the vaccines at no cost. Cox said the cost of the vaccine could have a “slight upward effect” on insurance premiums. isn’t expected to be renewed next year, which will lead to the formation of an official commercial market for COVID-19 vaccines, tests and treatments. But they also expect sales to fall rapidly after that. Much of the effect on premiums"will depend on the price per dose as well as the number of people who get vaccines and boosters," she added. Arthur Caplan, the head of medical ethics at NYU Langone Medical Center in New York City, said that the price for Pfizer’s vaccine is still relatively low. A recent Kaiser Family Foundation analysis said most people with private insurance won’t be expected to pay anything out of pocket for the vaccines, though the costs may eventually be baked into the price of health-insurance premiums, as is done with flu shots. regulators have authorized updated COVID-19 boosters, the first to directly target today's most common omicron strain. The price the company chose “makes sense,” he said, considering uptake of the new boosters is low. population has already received at least one dose of COVID-19 vaccine, according to the CDC. Around 20 million people ages 5 and up have received an updated Covid booster since the start of September, according to data released Thursday by the CDC. It’s the uninsured who may find it difficult to find free vaccines and boosters in the future. Pfizer said it also plans to provide free vaccines to people without insurance through its patient assistance program. Follow . It also bodes well for Moderna’s stock. The AP is solely responsible for all content.
Share:
0 comments

Comments (0)

Leave a Comment

Minimum 10 characters required

* All fields are required. Comments are moderated before appearing.

No comments yet. Be the first to comment!